Ongoing Assessment

At each visit, monitor all patients for1:

  • Weight, status of comorbidities, and achievement of goals
  • Adjustments/modifications to concomitant medications
  • Use of effective contraception, if applicable. Test for pregnancy on a monthly basis if patient is a female of reproductive potential
  • Heart rate: discontinue for sustained elevations
  • Emergence/worsening depression, suicidal thoughts or behaviors
  • Important side effects (eg, cognitive dysfunction, glaucoma, metabolic acidosis, kidney stones)
    • Consider lowering dose or discontinuing medication for patients who experience important side effects

After 12 weeks at recommended dose of 7.5 mg/46 mg1:

After additional 12 weeks following dose escalation to top dose of 15 mg/92 mg1:

  • If weight loss is less than 5% after 12 weeks, discontinue treatment
  • Discontinue top dose (15 mg/92 mg) gradually by taking a dose every other day for at least 1 week prior to stopping altogether, due to the possibility of precipitating a seizure with abrupt cessation of the drug

For more information, see the Qsymia Dosing and Management Checklist.

Qsymia is the only once-daily combination pill proven to significantly reduce weight1-5

Choose Qsymia as first-line choice for a range of overweight and obese patient types who need to achieve significant weight loss1-2

Review the Data

Choose Qsymia as first-line for obesity treatment1,2

1.2 MILLION QSYMIA RXS HAVE BEEN FILLED TO HELP PATIENTS ACHIEVE THEIR WEIGHT-LOSS GOALS1

Source: McKesson Specialty Health, 2015.

Learn More